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The earliest retrospective study of the COVID-19 
outbreak in Wuhan, China, published in the Lancet, was 
among one of the first clinical studies to identify older 
age as a significant risk factor for in-hospital mortality, 
suggesting that advanced chronological age may play an 
epidemiological role in patient clinical outcomes [1].   
 
Mortality was also associated with other co-morbidities, 
normally considered to be aging-associated diseases, 
such as diabetes or coronary heart disease, as well as a 
critical inflammatory mediator of the senescence-
associated secretory phenotype (SASP), namely IL-6 
[1].  
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ABSTRACT 
 
COVID-19, also known as SARS-CoV-2, is a new emerging zoonotic corona virus of the SARS (Severe Acute 
Respiratory Syndrome) and the MERS (Middle East Respiratory Syndrome) family. COVID-19 originated in China 
and spread world-wide, resulting in the pandemic of 2020. For some reason, COVID-19 shows a considerably 
higher mortality rate in patients with advanced chronological age. This begs the question as to whether there is 
a functional association between COVID-19 infection and the process of chronological aging. Two host 
receptors have been proposed for COVID-19. One is CD26 and the other is ACE-2 (angiotensin-converting 
enzyme 2). Interestingly, both CD26 and the angiotensin system show associations with senescence. Similarly, 
two proposed therapeutics for the treatment of COVID-19 infection are Azithromycin and Quercetin, both drugs 
with significant senolytic activity. Also, Chloroquine-related compounds inhibit the induction of the well-known 
senescence marker, Beta-galactosidase. Other anti-aging drugs should also be considered, such as Rapamycin 
and Doxycycline, as they behave as inhibitors of protein synthesis, blocking both SASP and viral replication. 
Therefore, we wish to speculate that the fight against COVID-19 disease should involve testing the hypothesis 
that senolytics and other anti-aging drugs may have a prominent role in preventing the transmission of the 
virus, as well as aid in its treatment. Thus, we propose that new clinical trials may be warranted, as several 
senolytic and anti-aging therapeutics are existing FDA-approved drugs, with excellent safety profiles, and would 
be readily available for drug repurposing efforts. As Azithromycin and Doxycycline are both commonly used 
antibiotics that inhibit viral replication and IL-6 production, we may want to consider this general class of 
antibiotics that functionally inhibits cellular protein synthesis as a side-effect, for the treatment and prevention 
of COVID-19 disease.  
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This specific association of COVID-19 fatality with 
advanced chronological age was directly validated by 
the CDC in the US population [2] and published in the 
Morbidity and Mortality Weekly Report (MMWR) on 
the 18th of March, as follows: “This first preliminary 
description of outcomes among patients with COVID-
19 in the United States indicates that fatality was 
highest in persons aged ≥85, ranging from 10% to 27%, 
followed by 3% to 11% among persons aged 65–84 
years, 1% to 3% among persons aged 55-64 years, <1% 
among persons aged 20–54 years, and no fatalities 
among persons aged ≤19 years”. 
What could be the biological mechanism(s) by which 
the COVID-19 virus preferentially targets patients 
with advanced chronological age?  
Two host receptors have been proposed for COVID-19. 
One is CD26 [3] and the other is ACE-2 (angiotensin-
converting enzyme 2) [4]. Interestingly, both CD26 and 
the angiotensin system show associations with 
senescence. For example, ACE-2 is a known inhibitor 
of cell proliferation and the angiotensin system is 
upregulated in both premature and replicative 
senescence [5,6]. Remarkably, CD26 is known to be a 
bonafide cell surface marker of senescent cells [7].  
Similarly, myofibroblasts (which are considered to be 
senescent and pro-fibrotic cells) also over-express 
CD26 and ACE-2 [8,9]. Senescent cells produce large 
amounts of inflammatory cytokines, as a result of the 
senescence-associated secretory phenotype (SASP), 
including IL-6. 
Interestingly, the host receptor for MERS-CoV, a 
highly-related corona virus, is CD26, also known as 
dipeptidyl-peptidase IV (DPP4) [10-12]. Genetic 
evidence, including functional studies of existing CD26 
human polymorphisms and humanized CD26 transgenic 
mouse animal models, has directly shown that CD26 is 
the functional host receptor for MERS-CoV, which is 
specifically required for host cell attachment, entry and, 
therefore, productive host cell infections, as well as 
species restrictions [10-12] Moreover, recent structural 
studies predict that the COVID-19 spike glycoproteins 
also directly interact with host cell CD26 [3]. 
Thus, one hypothesis is that the COVID-19 virus 
significantly increases mortality in patients with 
advanced chronological age, because these patients have 
an increased number of senescent lung cells, which are 
the host target for COVID-19 viral infection. 
Interestingly, senescent cells also show an increased 
propensity for enhanced protein synthesis, which is 
required to produce SASP inflammatory mediators, 
which would make senescent cells an ideal host target 
for efficient viral replication.  
Therefore, it would be predicted that senolytic drugs 
could have a beneficial effect for the treatment and/or 
prevention of COVID-19 disease. Is there any evidence 
to support this attractive hypothesis? 
Recently, a clinical trial was conducted using COVID-
19 positive hospitalized patients, which assessed 
COVID-19 virus production in response to treatment 
with two FDA-approved drugs, namely Hydroxy-
chloroquine (Plaquenil) and Azithromycin (Z-PAC) 
[13]. Hydroxy-chloroquine alone, at the standard 
dosages, was surprisingly effective in reducing COVID-
19 viral production. However, the combination of 
Hydroxy-chloroquine and Azithromycin appeared to be 
even more effective. The mechanism(s) by which this 
drug combination halts COVID-19 virus production 
remains unknown.  
What is the known relationship between Hydroxy-
chloroquine, Azithromycin and senescence?  
Chloroquine and its derivatives, such as Hydroxy-
chloroquine, alkalinize the pH in lysosomes, which 
accumulate in large numbers in senescent cells. This 
Chloroquine-induced alkalinization functionally 
prevents the induction and accumulation of one of the 
most widely-recognized markers of senescence, known 
as beta-galactosidase (Beta-Gal), a lysosomal enzyme 
[14]. Hydroxy-chloroquine is also used clinically for the 
treatment of chronic inflammatory diseases, such as 
Sjögren's syndrome, and it effectively reduces the 
salivary and serum levels of IL-6, a key component of 
the SASP [15].  
Azithromycin also has a key relationship with 
senescence [16]. Recent studies have shown that 
Azithromycin, and the closely related drug 
Roxithromycin, both act as senolytic drugs that can 
target and selectively remove senescent cells, with an 
efficiency of nearly 97% [16]. Interestingly, in patients 
with Cystic Fibrosis, Azithromycin is known to have an 
anti-fibrotic effect, which significantly extends their 
lifespan, by targeting myofibroblast cells (Discussed in 
Ref [16]). Cystic Fibrosis patients normally die from 
lung inflammation and fibrosis, resulting in lung 
stiffening and an inability to respire. Fibrosis is also 
known to be an age-related phenomenon, associated 
with increased numbers of myofibroblasts (senescent 
cells), which increases with chronological age.  
Azithromycin functionally acts as an anti-inflammatory 
drug and reduces SASP mediators, such as IL-1beta and 
IL-6 [17,18]. This may be due to Azithromycin’s high 
senolytic activity and/or inhibition of protein synthesis.   
Interestingly, Azithromycin also inhibits the replication 
of other viruses, such as Zika and Ebola [19-21]. If this 
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inhibitory activity reflects Azithromycin’s ability to 
inhibit protein synthesis, then other inhibitors of protein 
synthesis, such as Rapamycin, should be considered as 
well (see Supplementary Figure 1).  
Consistent with this hypothesis, Rapamycin has been 
shown to potently inhibit HIV-1 replication [22]. 
Moreover, Rapamycin shows key anti-aging properties 
and prevents the onset of senescence [23-25].  
Similarly, Doxycycline inhibits mammalian cell protein 
synthesis as an off-target side effect [26], effectively 
blocks replication of Dengue virus [27], reduces IL-6 
serum levels during viral infection [28] and behaves as 
an anti-aging drug [29]. Therefore, Doxycycline could 
provide another inexpensive, but very attractive, option 
for the treatment or prevention of COVID-19 infection. 
Finally, a recent study, using supercomputer-based in 
silico drug-docking to the COVID-19 viral spike protein 
identified Quercetin as a potential binding partner, to 
reduce virus-host interactions, with ACE-2 [30].  
Quercetin has also been identified as a dietary 
supplement with senolytic properties [31].   
Therefore, we propose that the clinical relationship 
between advanced chronological age and COVID-19 
mortality may suggest the use of senolytic or anti-aging 
drugs in COVID-19 disease prevention (Figure 1).  Of 
course, clinical trials will be necessary to test this 
attractive, but speculative, hypothesis experimentally.  
 
 
 
 
 
 
 
 
 
 
 
 
Fortunately, several promising senolytic and other anti-
aging drugs are already FDA-approved for other disease 
indications. This approach can significantly accelerate 
their clinical evaluation through drug repurposing, as 
they have already been evaluated for their clinical 
safety, in Phase I trials.  As such, these FDA-approved 
drugs can directly enter into Phase II clinical trials, to 
test their potential efficacy against COVID-19. 
Alternatively, in the United States, FDA-approved 
drugs can be medically-prescribed for an “off-label” 
use, at the discretion of the practicing physician.  
 
Interestingly, SARS-CoV, a close relative of COVID-19 
(SARS-CoV-2), also shows increased susceptibility in 
patients with advanced chronological age, which has 
been recapitulated in a mouse animal model of disease 
pathogenesis [32,33]. Briefly, in young mice (4-8 
weeks-old), the SARS-CoV infection is cleared very 
rapidly, which is accompanied by mild pneumonitis, 
without the activation of cytokine production. In 
contrast, in older mice (12-14-months-old), productive 
infection with SARS-CoV led to a more severe 
interstitial pneumonitis, with alveolar damage, 
significant fibrosis and scarring, as well as severe 
activation of cytokine production, including TNF-α, IL-
6, CCL-2, CCL-3, CXCL-10, and IFN-γ [32,33].  This 
latter mouse model more closely resembles the SARS-
CoV disease phenotype, observed in patients with 
advanced chronological age. Therefore, such a mouse 
model would also be useful for testing the efficacy of 
new therapies, specifically targeting the senescent cell  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. What is the relationship between COVID-19 and advanced chronological age? Here, we suggest that the COVID-19 
corona virus preferentially targets senescent lung cells, resulting in increased morbidity and mortality in the aging population. One 
possible solution for prevention/treatment would be the use of senolytics or other anti-aging drugs. Testing this hypothesis will require 
the necessary clinical trials, with a focus on drug repurposing.  
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population and SASP, for the repurposing of these 
FDA-approved anti-aging drugs.  
 
Disclaimer 
 
This perspective is intended for a professional audience, 
to stimulate new ideas and to aid the global efforts to 
develop effective treatments for COVID-19 disease. This 
article does not represent medical advice or 
recommendations to patients. The media should exercise 
caution and seek expert medical advice for interpretation, 
when referring to this article. 
Note Added in Proof 
While this Perspective was being reviewed, another 
clinical trial was published online, confirming the 
efficacy of Hydroxy-chloroquine and Azithromycin, for 
treating COVID-19 patients, in a larger cohort of 80 
patients. See the following article: 
Philippe Gautret, Jean-Christophe Lagier, Philippe 
Parola, Van Thuan Hoang, Line Meddeb, Jacques 
Sevestre, Morgane Mailhe, Barbara Doudier, Camille 
Aubry, Sophie Amrane, Piseth Seng, Marie Hocquart, 
Julie Finance, Vera Esteves Vieira, Hervé Tissot Dupont, 
Stéphane Honoré, Andreas Stein, Matthieu Million, 
Philippe Colson, Bernard La Scola, Véronique Veit, 
Alexis Jacquier, Jean-Claude Deharo, Michel Drancourt 
and Didier Raoult. Clinical and microbiological effect of 
a combination of hydroxychloroquine and azithromycin 
in 80 COVID-19 patients with at least a six-day follow 
up: an observational study. 
https://www.mediterranee-infection.com/wp-
content/uploads/2020/03/COVID-IHU-2-1.pdf 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figure 
 
Supplementary Figure 1. Inhibitor(s) of protein synthesis block inflammation and viral replication. Azithromycin, Doxycycline 
and Rapamycin are all FDA-approved drugs that behave as inhibitors of protein synthesis and experimentally have been shown to reduce 
inflammation and viral replication. Mechanistically, this is because cytokines and viruses are both made of proteins.  Both use the cellular 
ribosomes for protein translation. Inhibiting virus production should help to clinically reduce viral transmission to other patients.  
 
